CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
RAD001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00576680
NCT00576680Phase 2Completed
CompareCT.gov

Phase I/II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Dana-Farber Cancer Institute·interventional·Posted Dec 19, 2007·Updated Jul 9, 2020

In Brief

A Phase 2 clinical trial evaluating RAD001 and Temozolomide for Pancreatic Neuroendocrine Tumor. Completed, enrolled 43 participants across 3 sites.

Detailed Summary

This research study will test the safety of RAD001 in combination with temozolomide.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Neuroendocrine Tumor
CountriesUnited States
CollaboratorsBeth Israel Deaconess Medical Center, Brigham and Women's Hospital, Massachusetts General Hospital, Novartis, Schering-Plough

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 19, 2007
Enrollment StartMay 1, 2008
Primary CompletionMar 29, 2019
TodayJul 2, 2026
Enrollment to primary: 10.9 yearsPosted 18.5 years ago

Interventions

RAD001drug

Given orally once a day

Temozolomidedrug

Taken orally once a day for one week followed by a one-week break period